Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A

Recent pharmacogenetic evidence indicates that hepatic organic cation transporter (OCT) 1 can serve as the locus of drug-drug interactions (DDIs) with significant pharmacokinetic and pharmacodynamic consequences. We examined the impact of preincubation on the extent of OCT1 inhibition in transfected human embryonic kidney 293 (HEK293) cells. Following 30-minute preincubation with an inhibitor, approximately 50-fold higher inhibition potency was observed for cyclosporine A (CsA) against OCT1-mediated uptake of metformin compared with coincubation, with IC50 values of 0.43 ± 0.12 and 21.6 ± 4.5 µM, respectively. By comparison, only small shifts (≤2-fold) in preincubation IC50 versus coincubation were observed for quinidine, pyrimethamine, ritonavir, and trimethoprim. The shift in CsA OCT1 IC50 was substrate dependent since it ranged from >1.2- to 50.2-fold using different experimental substrates. The inhibition potential of CsA toward OCT1 was confirmed by fenoterol hepatocyte uptake experiment. Furthermore, no shift in CsA IC50 was observed with HEK293 cells transfected with OCT2 and organic anion transporter (OAT) 1 and OAT3. Short exposure (30 minutes) to 10 µM CsA produced long-lasting inhibition (at least 120 minutes) of the OCT1-mediated uptake of metformin in OCT1-HEK293 cells, which was likely attributable to the retention of CsA in the cells, as shown by the fact that inhibitory cellular concentrations of CsA were maintained long after the removal of the compound from the incubation buffer. The potent and persistent inhibitory effect after exposure to CsA warrants careful consideration in the design and interpretation of clinical OCT1 DDI studies. SIGNIFICANCE STATEMENT Preincubation of OATP1B1 and OATP1B3 with their inhibitor may result in the enhancement of the inhibitory potency in a cell-based assay. However, limited data are available on potentiation of OCT1 inhibition by preincubation, which is a clinically relevant drug transporter. For the first time, we observed a 50-fold increase in CsA inhibitory potency against OCT1-mediated transport of metformin following a preincubation step. The CsA preincubation effect on OCT1 inhibition is substrate dependent. Moreover, the inhibition potential of CsA toward OCT1 is confirmed by hepatocyte uptake experiment. This study delivers clear evidences about the potent and persistent inhibitory effect on OCT1 after exposure to CsA. Further studies are needed to assess the effect of CsA on OCT1 drug substrates in vivo.

[1]  Immunosuppressants , 2019, Reactions Weekly.

[2]  Imad Hanna,et al.  A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters , 2019, Drug Metabolism and Disposition.

[3]  Yan Zhang,et al.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance , 2018, Clinical pharmacology and therapeutics.

[4]  J. Brockmöller,et al.  OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil , 2018, Clinical pharmacology and therapeutics.

[5]  J. E. Park,et al.  Inhibition of Organic Anion Transporting Polypeptide 1B1 and 1B3 by Betulinic Acid: Effects of Preincubation and Albumin in the Media. , 2018, Journal of pharmaceutical sciences.

[6]  F. Faltraco,et al.  Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency , 2018, Clinical pharmacology and therapeutics.

[7]  Lei Zhang,et al.  Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions , 2018, Clinical pharmacology and therapeutics.

[8]  Yuichi Sugiyama,et al.  Preincubation‐dependent and long‐lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug‐drug interactions , 2017, Pharmacology & therapeutics.

[9]  Lei Zhang,et al.  Evaluation of transporters in drug development: Current status and contemporary issues☆ , 2017, Advanced drug delivery reviews.

[10]  J. Brockmöller,et al.  Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption , 2016, Pain.

[11]  Lei Zhang,et al.  Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1 , 2016, Journal of clinical pharmacology.

[12]  F. Faltraco,et al.  OCT1 mediates hepatic uptake of sumatriptan and loss‐of‐function OCT1 polymorphisms affect sumatriptan pharmacokinetics , 2016, Clinical pharmacology and therapeutics.

[13]  J. Brockmöller,et al.  Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1 , 2015, Genome Medicine.

[14]  K. Maeda,et al.  Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions , 2015, Drug Metabolism and Disposition.

[15]  K. Brouwer,et al.  Novel Mechanism of Impaired Function of Organic Anion-Transporting Polypeptide 1B3 in Human Hepatocytes: Post-Translational Regulation of OATP1B3 by Protein Kinase C Activation , 2014, Drug Metabolism and Disposition.

[16]  K. Takeuchi,et al.  Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. , 2013, Journal of pharmaceutical sciences.

[17]  L Zhang,et al.  Transporter Studies in Drug Development: Experience to Date and Follow‐Up on Decision Trees From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.

[18]  A. Galetin,et al.  Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2013, Pharmaceutical Research.

[19]  R. Kaiser,et al.  Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron , 2010, The Pharmacogenomics Journal.

[20]  A. Åsberg,et al.  Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin , 2010, Drug Metabolism and Disposition.

[21]  A. D. Rodrigues,et al.  Transporter Studies with the 3-O-Sulfate Conjugate of 17α-Ethinylestradiol: Assessment of Human Kidney Drug Transporters , 2010, Drug Metabolism and Disposition.

[22]  A. D. Rodrigues,et al.  Transporter Studies with the 3-O-Sulfate Conjugate of 17α-Ethinylestradiol: Assessment of Human Liver Drug Transporters , 2010, Drug Metabolism and Disposition.

[23]  M. Fraunholz,et al.  Rapid Modulation of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1, SLCO2B1) Function by Protein Kinase C-mediated Internalization* , 2010, The Journal of Biological Chemistry.

[24]  Y. Sugiyama,et al.  Long-Lasting Inhibition of the Transporter-Mediated Hepatic Uptake of Sulfobromophthalein by Cyclosporin A in Rats , 2009, Drug Metabolism and Disposition.

[25]  Manfred Kansy,et al.  Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model , 2008, Drug Metabolism and Disposition.

[26]  K. Giacomini,et al.  Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics , 2008, Clinical pharmacology and therapeutics.

[27]  Conrad C. Huang,et al.  Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  U. Brinkmann,et al.  Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. , 2002, Pharmacogenetics.

[29]  R. Kim,et al.  Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects , 2001, Clinical pharmacology and therapeutics.

[30]  A. Burgess,et al.  Modeling conformational changes in cyclosporin A , 1995, Protein science : a publication of the Protein Society.

[31]  N el Tayar,et al.  Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. , 1993, Journal of medicinal chemistry.

[32]  D. Faulds,et al.  Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders , 1993, Drugs.

[33]  D. Seebach,et al.  Complexation and medium effects on the conformation of cyclosporin A studied by NMR spectroscopy and molecular dynamics calculations. , 1990, Biochemical pharmacology.

[34]  M Rowland,et al.  Cyclosporin: measurement of fraction unbound in plasma , 1987, The Journal of pharmacy and pharmacology.

[35]  Y. Sugiyama,et al.  Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. , 2012, Drug metabolism and pharmacokinetics.

[36]  D. Faulds,et al.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. , 1993 .